The US Food and Drug Administration (FDA) approved Tekamlo® (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren) with the widely used calcium channel blocker, amlodipine1. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone1…

Novartis’ single pill combination of aliskiren and amlopidine - Tekamlo - has been approved by the Food and Drug Administration (FDA) for the treatment of hypertension. Data revealed that Tekamlo significantly reduced blood pressure compared to amlodipine or aliskiren (Tekturna) alone. The medication has been approved in tablet form…

Actelion Pharmaceuticals US, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company’s epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010…

A small amount of aspirin a day could help certain groups of pregnant women keep a potentially serious and sometimes fatal condition at bay. The National Institute for Health and Clinical Excellence (NICE) says this is just one of a number of ways to help prevent and treat hypertension (high blood pressure) before, during and after pregnancy. The condition is a leading cause of maternal death in the UK[1]…

STOCKHOLM (MedPage Today) — A daily coffee habit may counteract aortic stiffness in older adults with hypertension, researchers reported.

Behavioral researchers at MicroMass Communications have identified a metabolic mindset™ that could be the key to helping physicians, nurses and other healthcare educators successfully influence patients with type 2 diabetes, hypertension and high cholesterol to adopt healthier lifestyle changes such as losing weight, eating better, getting more exercise, and giving up cigarettes. Jessica Brueggeman, director of behavioral sciences at MicroMass, says the research has important health and economic implications, especially in the nation’s escalating battle against obesity…

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study. Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing…

Most weight loss programs try to motivate individuals with warnings of the long-term health consequences of obesity: increased risk for cancer, diabetes, hypertension, heart disease and asthma. New research suggests the immediate health benefits - such as reduced pain - may be the most effective motivator for helping obese individuals shed extra weight and commit to keeping it off…

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people’s vitamin D daily intake amount in order to maximize the vitamin’s contribution to reducing the frequency of a number of diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness……..

Boehringer Ingelheim announced that the European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA®. It will be indicated in adults whose blood pressure is not adequately controlled on amlodipine and is also indicated as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of TWYNSTA containing the same component doses…